Monash University Partners with Orio Therapeutics to Transform Regenerative Medicine
Tuesday, October 10, 2023
Monash University teams up with Orio Therapeutics in hybrid equity and licencing deal to revolutionise regenerative medicine through novel drug delivery technology. The newly developed technology enhances therapeutic protein delivery by ensuring controlled, gradual release and sustained dosing directly at the injection site. This advancement enables more effective therapeutic outcomes with reduced dosage requirements.
Many protein-based therapeutics in regenerative medicine face significant challenges due to inadequate delivery systems, often necessitating large therapeutic protein doses that quickly disperse from the injection site. This situation can lead to frequent, high-dose administrations, resulting in undesirable side effects and elevated treatment costs. By maintaining precise control over delivery, this technology ensures that the therapeutic remains concentrated at the injection site, where localised action is essential for tissue regeneration and repair.
This novel technology holds the potential to revolutionise the field of regenerative medicine, offering a groundbreaking approach to tissue regeneration and repair while addressing previously unmet medical needs and enhancing patient outcomes. Moreover, the versatility of this technology allows for the enhancement of nearly any protein therapeutic that could benefit from localised delivery.
This partnership aims to bring innovative drug delivery technology into the forefront of the regenerative medicine landscape and revolutionise patient care and drive advancements in the field.
